CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.
Enabling precision manufacturing of active pharmaceutical ingredients: workflow for seeded cooling continuous crystallisations
EPSRC CMAC CIM Workflow paper.... more
CMAC Welcomes Pfizer as Newest Partner
CMAC announces that Pfizer Inc has joined as a strategic member, alongside GSK, AZ, Novartis, Bayer, Takeda, Lilly and Roche..... more
Save the Date - CMAC Open Day 2018
Save the Date - CMAC Open Day 2018.... more